Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Core Insights - Eledon Pharmaceuticals reported significant advancements in its lead product, tegoprubart, an anti-CD40L antibody, which is being developed for immunosuppressive therapy in transplantation settings [2][5] - The company presented 24-month follow-up data from a Phase 1b long-term extension study, reinforcing the favorable safety and tolerability profile of tegoprubart [1][5] - Tegoprubart has received Orphan Drug designation from the FDA for preventing allograft rejection in liver transplantation, adding to its previous designations for pancreatic islet cell transplantation and ALS [5] Company Developments - Eledon treated over 100 patients across its transplantation programs, providing evidence that tegoprubart can address safety and efficacy issues with current transplant immunosuppression standards [2] - The company anticipates multiple milestones in 2026, including regulatory engagement for Phase 3 development in kidney transplantation and initiation of additional trials in islet and liver transplantation [2][5] Financial Performance - For the year ended December 31, 2025, Eledon's R&D expenses were $66.3 million, up from $52.0 million in 2024, driven by clinical development advancements and increased personnel [6] - General and administrative expenses decreased to $17.0 million in 2025 from $18.6 million in 2024, primarily due to lower stock-based compensation [7] - The net loss for 2025 was $45.6 million, or $0.52 per share, compared to a net loss of $36.2 million, or $0.66 per share, in 2024 [8][16]